Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy

Pharmacogenet Genomics. 2012 Nov;22(11):812-9. doi: 10.1097/FPC.0b013e328358d92b.

Abstract

The redox reaction of cytochrome P450 enzymes (CYP) is an important physiological and biochemical reaction in the human body, as it is involved in the oxidative metabolism of both endogenous and exogenous substrates. Cytochrome P450 oxidoreductase (POR) is the only obligate electron donor for all of the hepatic microsomal CYP enzymes. It plays a crucial role in drug metabolism and treatment by not only acting as an electron donor involved in drug metabolism mediated by CYP enzymes but also by directly inducing the transformation of some antitumor precursors. Studies have found that the gene encoding human POR is highly polymorphic, which is of considerable clinical significance as it affects the metabolism and curative effects of clinically used drugs. This review aims to discuss the effect of POR and its genetic polymorphisms on drug metabolism and therapy, as well as the potential mechanisms of POR pharmacogenetics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Inactivation, Metabolic / genetics
  • Liver / metabolism
  • NADPH-Ferrihemoprotein Reductase / genetics*
  • Pharmaceutical Preparations / metabolism*
  • Pharmacogenetics
  • Polymorphism, Genetic

Substances

  • Pharmaceutical Preparations
  • NADPH-Ferrihemoprotein Reductase